GlassScriptPhysician profile
Heaven Harris
NPI 1417566449
$5,143.91
in general payments reported to CMS, 2019-2025
23 companies · $840 in 2025
The $840 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $270 · 2021: $681 · 2022: $1,996 · 2023: $608 · 2024: $749 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178 · Entertainment: $18.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.35 |
| Entertainment | $18.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,415.30 | 2021-2025 | Precision 7, Precision7, Precision 1 |
| Allergan, INC. | $439.83 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $430.13 | 2020-2025 | Acuvue |
| Oyster Point Pharma, INC. | $422.24 | 2022-2024 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $311.03 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Biotissue Holdings INC. | $228.39 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $225.48 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $165.57 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $164.52 | 2020-2022 | |
| Dompe US, INC. | $156.54 | 2025 | Oxervate |
| Optos, INC. | $151.38 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Rxsight INC | $135.83 | 2022 | |
| Genentech USA, INC. | $132.59 | 2022 | |
| Abbvie INC. | $122.93 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $117.65 | 2024 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $116.12 | 2022 | |
| Sun Pharmaceutical Industries INC. | $104.57 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $97.44 | 2023 | Miebo |
| Astellas Pharma US INC | $82.63 | 2023 | |
| Coopervision INC. | $45.24 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $38.86 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.96 | 2024 | Acthar |
| Sight Sciences, INC. | $15.68 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heaven Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.